TPST
Tempest Therapeutics, Inc.Company Information
- Company Name
- Tempest Therapeutics, Inc.
- CIK
- CIK0001544227
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TPST: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TPST
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-24
- Last sale
- 2024-08-12
- Shares purchased (TTM)
- 462,964
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,024,557
- Shares outstanding
- 15,223,972
- Ownership
- 6.73%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -11.97%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1 | 2 | 8 | 8 | 14 | 22 | 30 | 22 | 31 | 32 | 39 | 11 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | ||||||
| Assets Current | 2 | 2 | 8 | 8 | 15 | 22 | 31 | 24 | 32 | 33 | 40 | 12 | ||||||
| Property Plant And Equipment Net | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 10 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 10 | 11 | 17 | 17 | 24 | 32 | 41 | 34 | 42 | 44 | 52 | 24 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 1 | 1 | 1 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 5 | 3 | 1 | 2 | 2 | 2 | 2 | ||||||
| Long Term Debt Current | - | - | 0 | 0 | 0 | 4 | 6 | 9 | 9 | 6 | 4 | 2 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Employee Related Liabilities Current | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | ||||||
| Interest And Dividends Payable Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 4 | 3 | 3 | 4 | 7 | 13 | 14 | 14 | 15 | 11 | 9 | 7 | ||||||
| Operating Lease Liability Noncurrent | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | - | - | 0 | 0 | 2 | 4 | 6 | 8 | ||||||
| Liabilities | 11 | 10 | 10 | 11 | 15 | 21 | 22 | 22 | 25 | 24 | 25 | 25 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 274 | 271 | 240 | 236 | 236 | 229 | 226 | 205 | 200 | 194 | 192 | 157 | ||||||
| Retained Earnings Accumulated Deficit | -275 | -270 | -233 | -229 | -226 | -218 | -207 | -193 | -183 | -173 | -165 | -158 | ||||||
| Stockholders Equity | -1 | 1 | 7 | 6 | 10 | 11 | 19 | 11 | 17 | 21 | 27 | -1 | ||||||
| Liabilities And Stockholders Equity | 10 | 11 | 17 | 17 | 24 | 32 | 41 | 34 | 42 | 44 | 52 | 24 | ||||||
| Deferred Finance Costs Current Net | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Deferred Finance Costs Net | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 16 | 14 | 5 | 4 | 4 | 4 | 3 | 27 | 24 | 22 | 22 | 14 | ||||||
| Shares Outstanding | 16 | 14 | 5 | 4 | 4 | 4 | 3 | 27 | 24 | 22 | 22 | 14 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTempest Therapeutics, Inc. (TPST) — SEC Financial Statements & Analysis
Tempest Therapeutics, Inc. (TPST) is a pharmaceutical preparations company, incorporated in DE. Tempest Therapeutics, Inc. trades on Nasdaq as: TPST. Tempest Therapeutics, Inc. (TPST)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Tempest Therapeutics, Inc. carries a market cap of $16.90M, a P/E ratio of -0.42x, a P/B ratio of -15.50x, an enterprise value of $15.68M, and an EV/EBITDA multiple of -0.39x. On profitability, it posts a Return on Equity (ROE) of -931.14% and a Return on Assets (ROA) of -237.25%. Per share, it reports EPS of $-2.66, diluted EPS of $-2.66, free cash flow per share of $-1.36, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -6.10% year-over-year and EPS growth of -76.54% year-over-year. On the balance sheet, it maintains a current ratio of 0.38x, a quick ratio of 0.18x, working capital of $-2.75M, a debt-to-equity ratio of -9.84x, a debt ratio of 1.11, an interest coverage ratio of -942.57x, free cash flow of $-20.73M (TTM), and net debt of $-1.22M. Figures sourced from SEC EDGAR.
- Market Cap
- $16.90M
- P/E TTM
- -0.42x
- EPS TTM
- $-2.66
- P/B TTM
- -15.50x
- ROE TTM
- -931.14%
- ROA TTM
- -237.25%
- Debt To Equity
- -9.84x
- Free Cash Flow TTM
- $-20.73M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Tempest Therapeutics, Inc. in?
Tempest Therapeutics, Inc. (TPST) operates in the Pharmaceutical Preparations industry.
What exchange does TPST trade on?
Tempest Therapeutics, Inc. (TPST) trades on the Nasdaq.
Where is Tempest Therapeutics, Inc. incorporated?
Tempest Therapeutics, Inc. is incorporated in DE.
When was Tempest Therapeutics, Inc. (TPST)'s most recent SEC filing?
Tempest Therapeutics, Inc. (TPST)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is TPST's market cap?
Tempest Therapeutics, Inc. (TPST) has a market capitalization of $16.90M as of 2026-06-30.
What is TPST's EPS (earnings per share)?
Tempest Therapeutics, Inc. (TPST)'s trailing twelve month EPS is $-2.66 as of 2026-06-30.
What is TPST's ROE (return on equity)?
Tempest Therapeutics, Inc. (TPST)'s trailing twelve month Return on Equity (ROE) is -931.14% as of 2026-06-30.
What is TPST's ROA (return on assets)?
Tempest Therapeutics, Inc. (TPST)'s trailing twelve month Return on Assets (ROA) is -237.25% as of 2026-06-30.
What is TPST's EV/EBITDA?
Tempest Therapeutics, Inc. (TPST)'s trailing twelve month EV/EBITDA is -0.39x as of 2026-06-30.